Skip to main content

On demand use of anakinra for attacks of familial Mediterranean fever (FMF)

Clinical Rheumatology volume 38, pages 577–581 (2019)Cite this article

Abstract

To evaluate the efficacy of on-demand use of anakinra in patients with crFMF. The Gazi FMF cohort was established in the year 2010, and from that date, 689 patients with FMF diagnosed according to the Tel Hashomer criteria were registered. Attack type, duration, severity, and their impact on life were collected either by disease diaries or a mobile phone application (FMF AIDD, AppStore, and Playstore). A retrospective cohort analysis was made from records of patients who have ever been treated with IL-1 inhibitors. A total of 78 patients were treated with IL-1 inhibitors in our cohort. Among these, 15 patients were identified who received on-demand anakinra. Rationale for on-demand use was prominent prodrome or trigger for attacks and patient’s personal claim. Six patients were switched from regular use and nine were directly started as on-demand use. All were using background colchicine in maximum tolerated doses. None of the patients had evidence of persistently elevated acute phase reactants or proteinuria. The median duration of on-demand anakinra use was 6 (3–36) months. Pre- and post- on-demand anakinra periods were compared. Patient reported attack severity (p = 0.002), duration (p = 0.001), frequency (p = 0.001), absenteeism (p = 0.002), and presenteeism (p = 0.002) were significantly improved. On-demand anakinra prevented progression of prodromes to full-blown attacks which was demonstrated by decrease in the rate of attack/prodrome ratio (p = 0.02). On-demand anakinra can be continued in ten subjects on long-term. On-demand anakinra significantly improved FMF attacks in certain patients which suggest this approach would be of benefit in daily practice in selected patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Heller H, Sohar ESL (1958) Familial Mediterranean fever. AMA Arch Intern Med 102:50–71

    Article  CAS  PubMed  Google Scholar 

  2. Sohar E, Gafni J, Pras M, Heller H (1967) Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 43:227–253

    Article  CAS  PubMed  Google Scholar 

  3. Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror Autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27:621–668. https://doi.org/10.1146/annurev.immunol.25.022106.141627

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ben-Chetrit E, Touitou I (2009) Familial Mediterranean fever in the world. Arthritis Rheum 61:1447–1453. https://doi.org/10.1002/art.24458

    Article  CAS  PubMed  Google Scholar 

  5. Karadag O, Tufan A, Yazisiz V, Ureten K, Yilmaz S, Cinar M, Akdogan A, Erdem H, Ozturk MA, Pay S, Dinc A (2013) The factors considered as trigger for the attacks in patients with familial Mediterranean fever. Rheumatol Int 33:893–897. https://doi.org/10.1007/s00296-012-2453-x

    Article  PubMed  Google Scholar 

  6. Lidar M, Yaqubov M, Zaks N et al (2006) The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. J Rheumatol 33:1089–1092

    PubMed  Google Scholar 

  7. Deger SM, Ozturk MA, Demirag MD, Aslan S, Goker B, Haznedaroglu S, Onat AM (2011) Health-related quality of life and its associations with mood condition in familial Mediterranean fever patients. Rheumatol Int 31:623–628. https://doi.org/10.1007/s00296-009-1334-4

    Article  PubMed  Google Scholar 

  8. Chae JJ, Aksentijevich I, Kastner DL (2009) Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol 146:467–478. https://doi.org/10.1111/j.1365-2141.2009.07733.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M, Amselem S, Gershoni-Baruch R, Touitou I, Ben-Chetrit E (2013) Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum 43:387–391. https://doi.org/10.1016/j.semarthrit.2013.04.011

    Article  PubMed  Google Scholar 

  10. Lidar M, Scherrmann J-M, Shinar Y et al (2004) Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 33:273–282

    Article  CAS  PubMed  Google Scholar 

  11. Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, Ozdogan H, Abu I, Gattorno M, Hawkins PN, Yuce S, Kallinich T, Bilginer Y, Kastner D, Carmona L (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75:644–651. https://doi.org/10.1136/annrheumdis-2015-208690

    Article  CAS  PubMed  Google Scholar 

  12. van der Hilst JC, Moutschen M, Messiaen PE, Lauwerys B, Vanderschueren S (2016) Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics 10:75–80. https://doi.org/10.2147/BTT.S102954

    Article  PubMed  PubMed Central  Google Scholar 

  13. Ozen S, Kone-Paut I, Gul A (2017) Colchicine resistance and intolerance in familial Mediterranean fever: definition, causes, and alternative treatments. Semin Arthritis Rheum 47:115–120. https://doi.org/10.1016/j.semarthrit.2017.03.006

    Article  CAS  PubMed  Google Scholar 

  14. Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S, Perski O, Bornstein G, Grossman C, Harari G, Lidar M, Livneh A (2017) Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 69:854–862. https://doi.org/10.1002/art.39995

    Article  CAS  PubMed  Google Scholar 

  15. Grimwood C, Despert V, Jeru I, Hentgen V (2015) On-demand treatment with anakinra: a treatment option for selected TRAPS patients. Rheumatology (United Kingdom) 54:1749–1751. https://doi.org/10.1093/rheumatology/kev111

    Article  Google Scholar 

  16. Bodar EJ, Kuijk LM, Drenth JPH, van der Meer JWM, Simon A, Frenkel J (2011) On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis 70:2155–2158. https://doi.org/10.1136/ard.2011.149922

    Article  CAS  PubMed  Google Scholar 

  17. Mitroulis I, Papadopoulos VP, Konstantinidis T, Ritis K (2008) Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Neth J Med 66:489–491

    CAS  PubMed  Google Scholar 

  18. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1879–1885. https://doi.org/10.1002/1529-0131(199710)40:10<1879::AID-ART23>3.0.CO;2-M

    Article  CAS  PubMed  Google Scholar 

  19. Piram M, Koné-Paut I, Lachmann HJ, Frenkel J, Ozen S, Kuemmerle-Deschner J, Stojanov S, Simon A, Finetti M, Sormani MP, Martini A, Gattorno M, Ruperto N (2014) Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis 73:2168–2173. https://doi.org/10.1136/annrheumdis-2013-203666

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Internal Medicine, Division of Rheumatology, Gazi University Faculty of Medicine, 06100, Ankara, Yenimahalle, Turkey

    Hakan Babaoglu, Ozkan Varan, Nuh Atas, Hasan Satis, Reyhan Salman, Mehmet Akif Ozturk, Seminur Haznedaroglu, Berna Goker & Abdurrahman Tufan

  2. Department of Internal Medicine, Division of Rheumatology, Erzurum Regional Research and Training Hospital, Health Science University, Erzurum, Turkey

    Hamit Kucuk

Authors
  1. Hakan Babaoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ozkan Varan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hamit Kucuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nuh Atas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hasan Satis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Reyhan Salman
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mehmet Akif Ozturk
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Seminur Haznedaroglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Berna Goker
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Abdurrahman Tufan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hakan Babaoglu.

Ethics declarations

Disclosures

None.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Babaoglu, H., Varan, O., Kucuk, H. et al. On demand use of anakinra for attacks of familial Mediterranean fever (FMF). Clin Rheumatol 38, 577–581 (2019). https://doi.org/10.1007/s10067-018-4230-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-018-4230-z

Keywords

  • Anakinra
  • Familial Mediterranean fever
  • On demand